Androgen Receptor Promotes Tamoxifen Agonist Activity by Activation of EGFR in ERα-Positive Breast Cancer

PURPOSE: Tamoxifen (Tam) resistance represents a significant clinical problem in estrogen receptor (ER) -positive breast cancer. We previously showed that decreased expression of Rho guanine nucleotide dissociation inhibitor (Rho GDI), a negative regulator of the Rho GTPase pathway, is associated wi...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Breast Cancer Res Treat
Glavni autori: Ciupek, Andrew, Rechoum, Yassine, Gu, Guowei, Gelsomino, Luca, Beyer, Amanda R., Brusco, Lauren, Covington, Kyle R., Tsimelzon, Anna, Fuqua, Suzanne A. W.
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4749407/
https://ncbi.nlm.nih.gov/pubmed/26487496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-015-3609-7
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items